Royal Jelly in acute leukemia
Phase 1
Completed
- Conditions
- Acute lymphoblastic lymphoma ( ALL ).Acute lymphoblastic leukemia [ALL]C91.0
- Registration Number
- IRCT20190106042260N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients with acute lymphoblastic leukemia who are in the complete maintenance and remission phase.
Having a normal heart echo
No history of asthma
No history of allergy to honey and its products
Exclusion Criteria
history of allergy to honey and its products
history of asthma
Cardiomyopathy and underlying heart problem
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total ?White blood cell count. Timepoint: from beginning ( before using a Jelly ), then every two week until 6 weeks. Method of measurement: Complete blood count (CBC).;Acute lymphocyte count. Timepoint: from beginning ( before using a Jelly ), then every two week until 6 weeks. Method of measurement: Complete blood count (CBC) /Differential Cell Exam.;Acute Neutrophil count. Timepoint: from beginning ( before using a Jelly ), then every two week until 6 weeks. Method of measurement: Complete blood count (CBC) /differential cell exam.
- Secondary Outcome Measures
Name Time Method